Lexicon Data Bolsters Pilavapadin's DPNP Path, Hints at Broader Neurologic Potential
Event summary
- Lexicon Pharmaceuticals presented additional Phase 2b data from the PROGRESS study at the American Academy of Neurology (AAN) meeting on April 22, 2026.
- The data supports the selection of pilavapadin 10mg as the optimal dose for Phase 3 development in diabetic peripheral neuropathic pain (DPNP).
- The study, which commenced in December 2023, enrolled 496 patients and evaluated three pilavapadin doses.
- Preclinical data also suggests pilavapadin may have broader applications in treating spasticity related to multiple sclerosis and spinal cord injury.
- Pilavapadin is an AAK1 inhibitor discovered through Lexicon’s Genome5000 program.
The big picture
Lexicon's focus on pilavapadin represents a bet on a novel mechanism (AAK1 inhibition) for treating neuropathic pain, a significant unmet medical need affecting millions of patients. The company's decision to advance the 10mg dose into Phase 3 signals confidence in the data, but the crowded DPNP market will require a differentiated clinical profile and robust commercial strategy for success. The potential expansion into spasticity indications could significantly broaden the drug’s addressable market if validated.
What we're watching
- Phase 3 Success
- The success of pilavapadin's Phase 3 trial will be critical for Lexicon, given the substantial market opportunity in DPNP and the need to demonstrate efficacy beyond Phase 2b results.
- AAK1 Validation
- Further preclinical and clinical validation of the AAK1 pathway's role in neurologic diseases will be necessary to support broader therapeutic applications beyond DPNP.
- Commercialization
- Lexicon's ability to navigate the complexities of commercializing a new DPNP treatment, particularly given existing therapies, will determine the drug's ultimate market penetration.
Related topics